Vamil Divan
Stock Analyst at Guggenheim
(4.84)
# 63
Out of 5,182 analysts
255
Total ratings
69.19%
Success rate
21.62%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $49 → $54 | $40.77 | +32.45% | 9 | Apr 14, 2026 | |
| ABBV AbbVie | Maintains: Buy | $242 → $249 | $208.38 | +19.49% | 29 | Apr 10, 2026 | |
| AMGN Amgen | Maintains: Neutral | $347 → $351 | $355.30 | -1.21% | 3 | Apr 9, 2026 | |
| ASMB Assembly Biosciences | Maintains: Buy | $39 → $43 | $29.24 | +47.06% | 3 | Apr 6, 2026 | |
| UNCY Unicycive Therapeutics | Maintains: Buy | $46 → $40 | $7.02 | +469.80% | 2 | Apr 2, 2026 | |
| PFE Pfizer | Maintains: Buy | $35 → $36 | $27.56 | +30.62% | 24 | Mar 24, 2026 | |
| JBIO Jade Biosciences | Maintains: Buy | $17 → $23 | $22.85 | +0.66% | 3 | Mar 11, 2026 | |
| MRK Merck & Co. | Maintains: Buy | $122 → $140 | $119.07 | +17.58% | 15 | Feb 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $234.18 | +2.49% | 19 | Jan 23, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $115 → $124 | $80.92 | +53.24% | 14 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $221 | $144.48 | +52.96% | 8 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $3.98 | +101.01% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.11 | +170.27% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $11 | $5.78 | +90.31% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $5.96 | +118.12% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.18 | +221.10% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.58 | +179.33% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $42.30 | +44.21% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $11.67 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $7.48 | +247.59% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.45 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.17 | -14.30% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $133.25 | -26.45% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $34.53 | -1.53% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.44 | +190.70% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $188.99 | -74.07% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $927.03 | -61.60% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.37 | -5.81% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $10.98 | +1,302.55% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $4.69 | +219.83% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.28 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $32.40 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $16.74 | -10.39% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $60.17 | +1.38% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.04 | +4,949.02% | 3 | Jan 17, 2018 |
Travere Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $49 → $54
Current: $40.77
Upside: +32.45%
AbbVie
Apr 10, 2026
Maintains: Buy
Price Target: $242 → $249
Current: $208.38
Upside: +19.49%
Amgen
Apr 9, 2026
Maintains: Neutral
Price Target: $347 → $351
Current: $355.30
Upside: -1.21%
Assembly Biosciences
Apr 6, 2026
Maintains: Buy
Price Target: $39 → $43
Current: $29.24
Upside: +47.06%
Unicycive Therapeutics
Apr 2, 2026
Maintains: Buy
Price Target: $46 → $40
Current: $7.02
Upside: +469.80%
Pfizer
Mar 24, 2026
Maintains: Buy
Price Target: $35 → $36
Current: $27.56
Upside: +30.62%
Jade Biosciences
Mar 11, 2026
Maintains: Buy
Price Target: $17 → $23
Current: $22.85
Upside: +0.66%
Merck & Co.
Feb 6, 2026
Maintains: Buy
Price Target: $122 → $140
Current: $119.07
Upside: +17.58%
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $234.18
Upside: +2.49%
ANI Pharmaceuticals
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $80.92
Upside: +53.24%
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $144.48
Upside: +52.96%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $3.98
Upside: +101.01%
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.11
Upside: +170.27%
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.78
Upside: +90.31%
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $5.96
Upside: +118.12%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.18
Upside: +221.10%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.58
Upside: +179.33%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $42.30
Upside: +44.21%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $11.67
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $7.48
Upside: +247.59%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.45
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.17
Upside: -14.30%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $133.25
Upside: -26.45%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $34.53
Upside: -1.53%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $3.44
Upside: +190.70%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $188.99
Upside: -74.07%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $927.03
Upside: -61.60%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.37
Upside: -5.81%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $10.98
Upside: +1,302.55%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $4.69
Upside: +219.83%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $29.28
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $32.40
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $16.74
Upside: -10.39%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $60.17
Upside: +1.38%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.04
Upside: +4,949.02%